Document Classification

Section Type: RESULTS

Text: At 18 months, PROs that were significantly worse in the ITAS groups when compared with STAS were hormone-treatment-related symptoms (HTRS ; STAS, 1020 [95 % CI 866-1175] ; ITAS, 1736 [1363-2108], p < 001 ; and ITAS plus zoledronic acid, 1914 [1543-2285], p < 001), sexual activity (STAS, 2638 [2350-2927] ; ITAS, 1440 [744-2136], p < 001 ; and ITAS plus zoledronic acid, 1634 [939-2328], p < 001), social function (STAS, 9031 [8789-9273] ; ITAS, 8735 [8152-9318], p = 009 ; and ITAS plus zoledronic acid, 8366 [7785-8948], p < 001), fatigue (STAS, 1705 [1458-1951] ; ITAS 2452 [1858-3046], p < 001 ; and ITAS plus zoledronic acid, 2426 [1833-3018], p < 001), and financial problems (STAS, 339 [129-548] ; ITAS, 897 [392-1402], p < 001 ; and ITAS plus zoledronic acid, 892 [389-1396], p < 001).